AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Subscribe To Our Newsletter & Stay Updated